Biopharmaceutical Practice Medical Affairs

Our Medical Affairs executive services help BioPharmaceutical companies strategically plan, organize and operate with greater efficiency.  Therefore, maximizing the value of their Medical Affairs function.



Service lines include:

4

 


Click the Tabs Below for Case Studies, White Papers, and Articles

 

Case Studies
Articles
Blog
  • Portfolio Prioritization – Oncology

    Situation: A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their focus. 

     

    Read this Case Study

  • Oncology Commercial Assessment – Melanoma

    Situation: A clinical-stage oncology company with a potentially ground-breaking technology requested Kineticos to help determine which tumor type(s) had the

     

    Read this Case Study

  • Product Search

    Situation: A drug delivery technology company identified an opportunity to generate additional revenue by acquiring products to further develop and

     

    Read this Case Study

  • Commercial Assessment

    Situation: A mid-sized biotech company evaluating their Phase II Metabolic asset requested that Kineticos provide a commercial and financial assessment

     

    Read this Case Study

  • Business Development and Licensing

    Situation: A publicly traded pharmaceutical company seeking a strategic partner for their IND-ready asset was in need of support with

     

    Read this Case Study

  • Diagnostics Partnering Support

    Situation: An emerging oncology diagnostics company was in need of a Business Development strategy and retained Kineticos to develop such

     

    Read this Case Study

  • What Can China Teach Us About CAR-T?

    What Can China Teach Us About CAR T is the final installment of our CAR-T series and discusses how China

     

    Read this Article

  • Staying the Course

    Written by Mark Osterman, Senior Vice President, Kineticos Kineticos recently announced Q4 2015 results of the Biopharma CEO Confidence Index,

     

    Read this Article

  • Cell and Gene Therapies: The Path to Commercialization

    Article Preview Regenerative Medicine holds enormous potential for treating and ameliorating many chronic conditions for which we do not yet

     

    Read this Article

  • Bridges and Barriers to Advancing CAR T Therapy

    One result of the Oncology explosion over the past 10 years has been the advent of CAR T therapy. In

     

    Read this Article

  • Growth by Acquisition in Life Sciences: Do You Have a Plan?

    Article Preview As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as

     

    Read this Blog Post

  • R&D Revolutionaries: Why the Actavis/Allergan Deal Takes a Stand for Biopharma’s True Roots in Innovation

    James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation?

     

    Read this Blog Post

  • Merck KGaA and Bayer Choose Opposite Strategies

    Article Preview Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent

     

    Read this Blog Post

  • Foundation Medicine and Clovis Expand Partnership

    Article Preview In April 2014, Foundation Medicine and Clovis Oncology announced the expansion of their partnership by developing a companion

     

    Read this Blog Post

  • Role of Companion Diagnostics in Immuno-oncology Race Unfolding

    Article Preview Important oncology events, including ASCO and ESMO, have recently displayed the fruits of the huge investment drug companies

     

    Read this Blog Post

  • Bayer to Divest Plastics Unit to Improve R&D, Acquisition Capacity

    Article Preview As reported by Bloomberg and the Wall Street Journal, Bayer is expected to announce plans to sell its

     

    Read this Blog Post

Subscribe to our internal think tank, Kineticos Research Institute